Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biosimilars | Emerging Biosimilars | Immunology | Inflectra/Renflexis | Wave 3 | US | 2018

Login to access report north_east
Contact sales account_box

Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. Merck & Co.’s Renflexis (infliximab-abda) subsequently launched in July 2017. Waves 1 and 2 of this series track Inflectra’s awareness and uptake since launch, while Wave 3 also incorporates Renflexis. Along with awareness, familiarity, and perceptions of biosimilars, our research explores the drivers and barriers behind uptake of both Inflectra and Renflexis. Promotional efforts are also explored, as well as prescriber and nonprescriber profiles, and benchmarking comparisons against other available biosimilars, to better understand the dynamics of the U.S. biosimilars market.

Questions Answered

  •  Are U.S. physicians aware of Inflectra and Renflexis?
  • What are the drivers to prescribing an infliximab biosimilar? What is the level of Inflectra and Renflexis use, and how is that changing over time?
  • Are physicians’ opinions of biosimilars changing?
  • Have physicians experienced pressures to prescribe Inflectra or Renflexis to patients?
  • What promotional messages are sales representatives employing for Inflectra, Renflexis, and Remicade?
  • How does formulary placement of Inflectra and Renflexis compare with Remicade, and does this change over time?

Scope:

  • Markets covered: United States.
  • Primary research: Survey of 92 U.S. rheumatologists, gastroenterologists, and dermatologists.

Key Companies Mentioned:

  • Celltrion.
  • Johnson & Johnson/Janssen.
  • Merck & Co.
  • Pfizer.
  • Samsung Bioepis.

Key Drugs Mentioned:

  • Remicade (infliximab).
  • Inflectra (infliximab-dyyb).
  • Renflexis (infliximab-abda).
  • Enbrel (etanercept).
  • Humira (adalimumab).
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
north_east
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
north_east
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
north_east
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
north_east
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east